Table 3

Clinical characteristics of TFL cohort

All TFL patients (n = 155)
(No.)(%)
Year of FL diagnosis   
 <2003 104 67 
 ≥2003 51 33 
Year of TFL diagnosis   
 <2003 59 38 
 ≥2003 96 62 
Antecedent FL grade   
 Grade 1 or 2 135 87 
 Grade 3A 20 13 
Time to transformation (y)   
 ≤5 98 63 
 5-10 39 25 
 >10 18 12 
Age at TFL diagnosis (y)   
 ≤60 65 42 
 >60 90 58 
First line treatment of FL   
 Single-agent chemo 34 24 
 Multi-agent chemo* 22 15 
 Multi-agent chemo + rituximab 14 10 
 Radiation or surgery 21 15 
 Observation 52 36 
 N/A 12 — 
Initial treatment after transformation   
 Multi-agent chemo 46 32 
 Multi-agent chemo§ + rituximab 82 56 
 Other 18 12 
 N/A — 
Hematopoietic stem cell transplant   
 Autologous 12 
 Allogeneic 
 None 133 90 
 N/A — 
Rituximab before transformation   
 No 120 79 
 Yes 32 21 
 N/A — 
Rituximab after transformation   
 No 61 40 
 Yes 91 60 
 N/A — 
All TFL patients (n = 155)
(No.)(%)
Year of FL diagnosis   
 <2003 104 67 
 ≥2003 51 33 
Year of TFL diagnosis   
 <2003 59 38 
 ≥2003 96 62 
Antecedent FL grade   
 Grade 1 or 2 135 87 
 Grade 3A 20 13 
Time to transformation (y)   
 ≤5 98 63 
 5-10 39 25 
 >10 18 12 
Age at TFL diagnosis (y)   
 ≤60 65 42 
 >60 90 58 
First line treatment of FL   
 Single-agent chemo 34 24 
 Multi-agent chemo* 22 15 
 Multi-agent chemo + rituximab 14 10 
 Radiation or surgery 21 15 
 Observation 52 36 
 N/A 12 — 
Initial treatment after transformation   
 Multi-agent chemo 46 32 
 Multi-agent chemo§ + rituximab 82 56 
 Other 18 12 
 N/A — 
Hematopoietic stem cell transplant   
 Autologous 12 
 Allogeneic 
 None 133 90 
 N/A — 
Rituximab before transformation   
 No 120 79 
 Yes 32 21 
 N/A — 
Rituximab after transformation   
 No 61 40 
 Yes 91 60 
 N/A — 

Chemo, chemotherapy; N/A, not available.

*

Ten patients out of 22 were treated with anthracycline-containing regimens.

Three patients out of 14 were treated with cyclophosphamide-doxorubicin-vincristine-prednisone and rituximab (or CHOP-R), and 11 out of 14 with cyclophosphamide-vincristine-prednisone and rituximab.

Forty-one patients out of 46 were treated with anthracycline-containing regimens.

§

Seventy-seven patients out of 82 were treated with CHOP-R.

Close Modal

or Create an Account

Close Modal
Close Modal